# US 2013/0273079 A1 · Ultraconserved Regions Encoding ncRNAs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0273079 A1
- Document ID: US20130273079A1
- Status: Published application
- Kind: A1
- Application number: 13/910,410
- Filed: 2013-06-05
- Published: 2013-10-17
- Earliest claimed: 2007-08-03
- Assignees: The Ohio State University
- Applicants: The Ohio State University
- Inventors: Carlo M. Croce
- Web page: https://patentgrep.com/patent/US20130273079A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2320/10: in screening processes
- C12N 2320/11: for the determination of target sites, i.e. of active nucleic acids
- C12N 2330/10: naturally occurring
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Described herein are methods for differentiate human cancers comprising using one or more transcribed ultraconserved regions (T-UCR) expression profiles where the association between the genomic location of UCRs and the analyzed cancer-related genomic elements is highly statistically significant and comparable to that reported for miRNAs.

## Claims

### Claim 1

A method of diagnosing whether a subject has, or is at risk for developing, a cancer linked to a cancer-associated chromosomal feature, comprising evaluating the status in the subject of at least one UCR gene located in close proximity to the cancer-associated chromosomal feature, by analyzing the at least one UCR gene in the test sample for a deletion, mutation or amplification, wherein detection of a deletion, mutation and/or amplification in the UCR gene as compared to the corresponding UCR gene in the control sample is indicative of the subject either having, or being at risk for developing, the cancer.

### Claim 2

A method to identify a relative risk in a vertebrate for developing a cancer, comprising:
(a) obtaining a nucleic acid-containing test sample from a vertebrate subject,
(b) measuring, by laboratory analysis, a level of at least one transcribed ultra-conserved regions (T-UCR),
(c) identifying whether the test sample expresses at least one T-UCR,
(d) determining the relative risk for developing the cancer by comparing the at least one T-UCR measured level to the level of a corresponding T-UCR in a control sample,
wherein an alteration in the level of at least one T-UCR in the test sample, relative to the level of a corresponding T-UCR in a control sample, is indicative of the subject either having, or being at risk for developing the cancer.

### Claim 3 (depends on 2)

The method of claim 2, further comprising:
(e) measuring the level of at least one miR in the test sample from said subject,
wherein an alteration in the level of the miR in the test sample, relative to the level of a corresponding miR in a control sample, is indicative of the subject either having, or being at risk for developing the cancer.

### Claim 4 (depends on 2)

The method of claim 2, wherein the cancer is selected from the group consisting of: bladder cancer; esophageal cancer; lung cancer; stomach cancer; kidney cancer; cervical cancer; ovarian cancer; breast cancer; lymphoma; Ewing sarcoma; hematopoietic tumors; solid tumors; gastric cancer; colorectal cancer; brain cancer; epithelial cancer; nasopharyngeal cancer; uterine cancer; hepatic cancer; hepatocellular carcinoma; head-and-neck cancer; renal cancer; male germ cell tumors; malignant mesothelioma; myelodysplastic syndrome; pancreatic or biliary cancer; prostate cancer; thyroid cancer; urothelial cancer; renal cancer; Wilm's tumor; small cell lung cancer; melanoma; skin cancer; osteosarcoma; neuroblastoma; leukemia (acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia); glioblastoma multiforme; medulloblastoma; lymphoplasmacytoid lymphoma; and rhabdomyosarcoma.

### Claim 5 (depends on 2)

The method of claim 2, wherein the at least one T-URC is selected from the group consisting of: uc.29A, uc.47, uc.73A, uc.111, uc.112, uc.134A, uc.135, uc.160, uc.206, uc.215, uc.230, uc.233, uc.246, uc.269A, uc.291, uc.292, uc.339, uc.341, uc.346A, uc.347, uc.348, uc.349A, uc.350, uc.351, uc.352, uc.353, uc.388, uc.399, and uc.420.

### Claim 6 (depends on 2)

The method of claim 2, wherein the test sample is derived from a cancer-associated body fluid or tissue.

### Claim 7 (depends on 2)

The method of claim 2, wherein the test sample comprises tumor cells obtained from the patient.

### Claim 8 (depends on 3)

The method of claim 3, wherein the method further comprises: correlating miRNA::T-UCR interaction.

### Claim 9 (depends on 1)

The method of claim 1, wherein the cancer-associated chromosomal feature is selected from the group consisting of: a cancer-associated genomic region; a chromosomal fragile site; a human papillomavirus integration site; and a homeobox gene or gene cluster.

### Claim 10 (depends on 1)

The method of claim 1, wherein the UCR gene is selected from the group consisting of: a cluster of seven UCRs of uc.347 through uc.353; and combinations thereof.

### Claim 11

A method of diagnosing whether a subject has, or is at risk for developing, a cancer, comprising: (1) reverse transcribing RNA from a test sample obtained from the subject to provide a set of target oligodeoxynucleotides; (2) hybridizing the target oligodeoxynucleotides to a microarray comprising one or more UCR specific probe oligonucleotides to provide a hybridization profile for the test sample; and (3) comparing the test sample hybridization profile to a hybridization profile generated from a control sample, and (4) diagnosing the subject as having or at risk for developing cancer if the test sample shows an alteration in the signal as compared to the control.

### Claim 12 (depends on 11)

The method of claim 11, wherein the cancer is selected from the group consisting of: bladder cancer; esophageal cancer; lung cancer; stomach cancer; kidney cancer; cervical cancer; ovarian cancer; breast cancer; lymphoma; Ewing sarcoma; hematopoietic tumors; solid tumors; gastric cancer; colorectal cancer; brain cancer; epithelial cancer; nasopharyngeal cancer; uterine cancer; hepatic cancer; hepatocellular carcinoma; head-and-neck cancer; renal cancer; male germ cell tumors; malignant mesothelioma; myelodysplastic syndrome; pancreatic or biliary cancer; prostate cancer; thyroid cancer; urothelial cancer; renal cancer; Wilm's tumor; small cell lung cancer; melanoma; skin cancer; osteosarcoma; neuroblastoma; leukemia (acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia); glioblastoma multiforme; medulloblastoma; lymphoplasmacytoid lymphoma; and rhabdomyosarcoma.

### Claim 13 (depends on 11)

The method of claim 11, further comprising identifying a potential for the initiation or development of at least one cancer-related disease in a subject, comprising identifying the presence in a test sample of a composition of matter comprising an isolated T-UCR associated with cancer, wherein said association is statistically significant, and the composition is a marker for assessing one or more metabolic pathways that contribute to at least one of initiation, progression, severity, pathology, aggressiveness, grade, activity, disability, mortality, morbidity, disease sub-classification or other underlying pathogenic or pathological feature of at least one cancer-related disease.

### Claim 14

A method of treating cancer in a subject, comprising:
(1) providing a subject who has a cancer associated with a cancer-associated chromosomal feature, in which at least one isolated UCR gene product from a UCR gene located in close proximity to the cancer-associated chromosomal feature is down-regulated or up-regulated in cancer cells of the subject as compared to control cells; and
(2) (a) when the at least one isolated UCR gene product is down-regulated in the cancer cells, administering to the subject an effective amount of at least one isolated UCR gene product from the at least one UCR gene, such that proliferation of cancer cells in the subject is inhibited; or (b) when the at least one isolated UCR gene product is up-regulated in the cancer cells, administering to the subject an effective amount of at least one compound for inhibiting expression of the at least one UCR gene, such that proliferation of cancer cells in the subject is inhibited.

### Claim 15 (depends on 14)

The method of claim 14, wherein the cancer-associated chromosomal feature is selected from the group consisting of a cancer-associated genomic region, and a chromosomal fragile site.

### Claim 16

A cDNA that is complementary to a T-UCR selected from the group consisting essentially of: uc.347; uc.348; uc.349; uc.350; uc.351; uc352; uc.353; uc.269A(N), uc.160(N), uc.215(N), uc.346A(P); uc.348(N); and uc.73(P).

### Claim 17

A pharmaceutical composition comprising a UCR gene product or complement and a pharmaceutically-acceptable carrier, wherein the isolated UCR gene product or complement is from a UCR gene located in close proximity to a cancer-associated chromosomal feature.

### Claim 18 (depends on 17)

The pharmaceutical composition of claim 17, wherein the cancer-associated chromosomal feature is selected from the group consisting of a cancer-associated genomic region, and a chromosomal fragile site.

### Claim 19

A pharmaceutical composition for treating a cancer, comprising
at least one UCR expression-inhibition compound, and
a pharmaceutically-acceptable carrier,
wherein the at least one UCR expression-inhibition compound is specific for a UCR gene product selected from the group consisting of: a cluster of seven UCRs of uc.347 through uc.353, and combinations thereof.

### Claim 20 (depends on 19)

The pharmaceutical composition of claim 19, wherein the at least one UCR expression-inhibition compound is specific for a UCR gene product that is up- or down-regulated in cancer cells relative to control cells.

### Claim 21

A computer-assisted method for evaluating the presence, absence, nature or extent of a cancer-related disease in a subject, comprising:
(1) providing a computer comprising a model or algorithm for classifying data from a sample obtained from the subject,
wherein the classification includes analyzing the data for the presence, absence or amount of at least one marker, and
wherein the marker comprises one or more UCR genes or gene products, provided that the UCR gene or gene product has been shown to be statistically significant in such association with cancer-related disease;
(2) inputting data from the biological sample obtained from the subject; and,
(3) classifying the biological sample to indicate the presence, absence, nature or extent of a cancer-related disease.
